

1. Sales January to September 2005 and 2004

| January – September | 2005 | 2004 | % change | |
|--------------------------|---------------|---------------|------------|---------------------|
| | CHF m | CHF m | In CHF | In local currencies |
| Pharmaceuticals Division | 19,434 | 16,132 | +20 | +22 |
| Roche Pharmaceuticals | 12,169 | 10,523 | +16 | +16 |
| Genentech | 4,632 | 3,287 | +41 | +45 |
| Chugai | 2,633 | 2,322 | +13 | +15 |
| Diagnostics Division | 6,008 | 5,763 | +4 | +4 |
| Roche Group | 25,442 | 21,895 | +16 | +17 |

2. Quarterly local sales growth by Division in 2004 and 2005

| | Q4 2004 vs. Q4 2003 | Q1 2005 vs. Q1 2004 | Q2 2005 vs. Q2 2004 | Q3 2005 vs. Q3 2004 |
|--------------------------|------------------------|------------------------|------------------------|------------------------|
| Pharmaceuticals Division | +5 | +22 | +21 | +21 |
| Roche Pharmaceuticals | -2 | +11 | +18 | +17 |
| Genentech | +48 | +54 | +41 | +42 |
| Chugai | -8 | +32 | +8 | +7 |
| Diagnostics Division | +6 | +4 | +4 | +6 |
| Roche Group | +6 | +17 | +17 | +17 |

3. Quarterly sales by Division in 2004 and 2005

| CHF millions | Q3 2004 | Q4 2004 | Q1 2005 | Q2 2005 | Q3 2005 |
|--------------------------|--------------|--------------|--------------|--------------|--------------|
| Pharmaceuticals Division | 5,485 | 5,563 | 6,155 | 6,497 | 6,782 |
| Roche Pharmaceuticals | 3,483 | 3,447 | 3,859 | 4,119 | 4,191 |
| Genentech | 1,235 | 1,235 | 1,341 | 1,526 | 1,765 |
| Chugai | 767 | 881 | 955 | 852 | 826 |
| Diagnostics Division | 1,884 | 2,064 | 1,935 | 2,035 | 2,038 |
| Roche Group | 7,369 | 7,627 | 8,090 | 8,532 | 8,820 |

4. Top 20 Pharmaceuticals Division product sales¹ and local growth² in first nine months of 2005:
US, Japan and Europe/Rest of World

| | Total | | US | | Japan | | Europe/RoW | |
|------------------------------------|-------|------|-------|------|-------|------|------------|-------|
| | CHF m | % | CHF m | % | CHF m | % | CHF m | % |
| MabThera/Rituxan | 3,001 | 22% | 1,725 | 16% | 142 | 6% | 1,134 | 35% |
| Neo Recormon/Epogin | 1,650 | 7% | - | - | 580 | 3% | 1,070 | 9% |
| Herceptin | 1,442 | 38% | 610 | 41% | 88 | 17% | 744 | 38% |
| Cellcept | 1,241 | 18% | 577 | 23% | 20 | 21% | 644 | 14% |
| Avastin | 1,093 | 148% | 949 | 118% | - | - | 144 | 2935% |
| Pegasys | 1,030 | 17% | 357 | 5% | 65 | 37% | 608 | 24% |
| Tamiflu | 859 | 263% | 183 | 297% | 265 | 223% | 411 | 279% |
| Rocephin | 766 | -21% | 442 | -23% | 44 | 20% | 280 | -21% |
| Xeloda | 568 | 47% | 214 | 64% | 22 | 35% | 332 | 39% |
| Xenical | 474 | 4% | 73 | -1% | - | - | 401 | 5% |
| Kytril | 365 | 11% | 147 | 14% | 98 | 11% | 120 | 7% |
| Nutropin/Protropin | 348 | 7% | 339 | 7% | - | - | 9 | -5% |
| Copegus | 320 | 10% | 149 | -10% | - | - | 171 | 36% |
| Pulmozyme | 286 | 15% | 169 | 20% | - | - | 117 | 7% |
| Cymevene/Valcyte | 285 | 17% | 145 | 8% | - | - | 140 | 28% |
| Xolair | 285 | 82% | 285 | 82% | - | - | - | - |
| Neutrogin | 266 | 14% | - | - | 266 | 14% | - | - |
| Tarceva | 246 | - | 234 | - | - | - | 12 | - |
| Dilatrend | 246 | -15% | - | - | - | - | 246 | -15% |
| Activase/TNKase | 223 | 8% | 197 | 9% | - | - | 26 | -3% |
| New products not covered in Top 20 | | | | | | | | |
| Fuzeon | 178 | 49% | 89 | 22% | - | - | 89 | 95% |
| Raptiva | 87 | 87% | 87 | 87% | - | - | - | - |
| Evista | 69 | 201% | - | - | 69 | 201% | - | - |
| Renagel | 41 | 26% | - | - | 41 | 26% | - | - |
| Boniva | 35 | - | 34 | - | - | - | 1 | - |

¹ Roche Pharmaceuticals, Genentech and Chugai combined

² versus first nine months of 2004

5. Top 20 Pharmaceuticals Division quarterly local product sales growth¹ in 2004 and 2005

| | Q4 2004 vs. Q4 2003 | Q1 2005 vs. Q1 2004 | Q2 2005 vs. Q2 2004 | Q3 2005 vs. Q3 2004 |
|--------------------|------------------------|------------------------|------------------------|------------------------|
| MabThera/Rituxan | 20% | 24% | 23% | 18% |
| NeoRecormon/Epogin | 1% | 7% | 8% | 6% |
| Herceptin | 25% | 23% | 31% | 57% |
| Cellcept | 3% | 4% | 25% | 28% |
| Avastin | - | 476% | 112% | 107% |
| Pegasys | 24% | 15% | 22% | 15% |
| Tamiflu | -69% | 302% | 707% | 148% |
| Rocephin | -5% | -6% | -5% | -54% |
| Xeloda | 39% | 48% | 50% | 44% |
| Xenical | -5% | 4% | 0% | 9% |
| Kytril | 11% | 0% | 18% | 14% |
| Nutropin/Protropin | 10% | 7% | 10% | 3% |
| Copegus | 13% | 5% | 15% | 9% |
| Pulmozyme | 3% | 10% | 20% | 15% |
| Cymevene/Valcyte | 26% | 2% | 29% | 22% |
| Xolair | 230% | 128% | 88% | 51% |
| Neutrogen | 7% | 9% | 13% | 20% |
| Tarceva | - | - | - | - |
| Dilatrend | -27% | -19% | -13% | -12% |
| Activase/TNKase | 5% | 12% | 3% | 9% |

¹ Roche Pharmaceuticals, Genentech and Chugai combined

6. Pharmaceuticals Division quarterly local product sales growth¹ US in 2004 and 2005

| | Q4 2004 vs. Q4 2003 | Q1 2005 vs. Q1 2004 | Q2 2005 vs. Q2 2004 | Q3 2005 vs. Q3 2004 |
|--------------------|------------------------|------------------------|------------------------|------------------------|
| MabThera/Rituxan | 8% | 19% | 16% | 14% |
| NeoRecormon/Epogin | - | - | - | - |
| Herceptin | 18% | 19% | 29% | 70% |
| Cellcept | -7% | -8% | 33% | 52% |
| Avastin | - | 432% | 85% | 78% |
| Pegasys | -3% | -9% | 19% | 9% |
| Tamiflu | -72% | - | 493% | 132% |
| Rocephin | 5% | 1% | 5% | -75% |
| Xeloda | 72% | 74% | 72% | 51% |
| Xenical | -37% | -1% | -14% | 20% |
| Kytril | 20% | -9% | 33% | 20% |
| Nutropin/Protropin | 11% | 7% | 10% | 3% |
| Copegus | -24% | -28% | 4% | -2% |
| Pulmozyme | 5% | 16% | 28% | 17% |
| Cymevene/Valcyte | 35% | -9% | 20% | 17% |
| Xolair | 230% | 128% | 88% | 51% |
| Neutrogin | - | - | - | - |
| Tarceva | - | - | - | - |
| Dilatrend | - | - | - | - |
| Activase/TNKase | 6% | 14% | 5% | 10% |

¹ Roche Pharmaceuticals and Genentech combined

7. Pharmaceuticals Division quarterly local product sales growth Japan¹ in 2004 and 2005

| | Q4 2004 vs. Q4 2003 | Q1 2005 vs. Q1 2004 | Q2 2005 vs. Q2 2004 | Q3 2005 vs. Q3 2004 |
|--------------------|------------------------|------------------------|------------------------|------------------------|
| MabThera/Rituxan | 15% | 7% | 11% | 1% |
| NeoRecormon/Epogin | 0% | 2% | 5% | 2% |
| Herceptin | 18% | 19% | 18% | 15% |
| Cellcept | 20% | 20% | 26% | 18% |
| Avastin | - | - | - | - |
| Pegasys | 1190% | 135% | 33% | 4% |
| Tamiflu | -87% | 209% | - | - |
| Rocephin | 2% | 33% | 13% | 17% |
| Xeloda | 28% | 41% | 38% | 27% |
| Xenical | - | - | - | - |
| Kytril | 0% | 14% | 10% | 10% |
| Nutropin/Protropin | - | - | - | - |
| Copegus | - | - | - | - |
| Pulmozyme | - | - | - | - |
| Cymevene/Valcyte | - | - | - | - |
| Xolair | - | - | - | - |
| Neutrogen | 7% | 9% | 13% | 20% |
| Tarceva | - | - | - | - |
| Dilatrend | - | - | - | - |
| Activase/TNKase | - | - | - | - |

¹ Chugai

8. Pharmaceuticals Division quarterly local product sales growth Europe/Rest of World¹ in 2004 and 2005

| | Q4 2004 vs. Q4 2003 | Q1 2005 vs. Q1 2004 | Q2 2005 vs. Q2 2004 | Q3 2005 vs. Q3 2004 |
|--------------------|------------------------|------------------------|------------------------|------------------------|
| MabThera/Rituxan | 51% | 36% | 39% | 29% |
| NeoRecormon/Epogin | 2% | 10% | 10% | 9% |
| Herceptin | 34% | 26% | 34% | 51% |
| Cellcept | 14% | 14% | 19% | 9% |
| Avastin | - | - | - | 1755% |
| Pegasys | 33% | 29% | 23% | 20% |
| Tamiflu | 103% | 361% | 654% | 158% |
| Rocephin | -22% | -20% | -22% | -23% |
| Xeloda | 23% | 36% | 39% | 41% |
| Xenical | 5% | 5% | 3% | 7% |
| Kytril | 9% | 4% | 10% | 9% |
| Nutropin/Protropin | 4% | -5% | -3% | -6% |
| Copegus | 120% | 61% | 29% | 22% |
| Pulmozyme | 1% | 2% | 10% | 11% |
| Cymevene/Valcyte | 15% | 19% | 39% | 27% |
| Xolair | - | - | - | - |
| Neutrogin | - | - | - | - |
| Tarceva | - | - | - | - |
| Dilatrend | -27% | -19% | -13% | -12% |
| Activase/TNKase | -5% | -3% | -11% | 6% |

¹ Roche Pharmaceuticals

9. Top Pharmaceuticals Division quarterly product sales^{1,2} in 2004 and 2005

| CHF millions | Q3 2004 | Q4 2004 | Q1 2005 | Q2 2005 | Q3 2005 |
|---|---------|---------|---------|---------|---------|
| MabThera/Rituxan | 877 | 877 | 929 | 1,015 | 1,057 |
| NeoRecormon/Epogin | 528 | 534 | 516 | 570 | 564 |
| Herceptin | 373 | 378 | 391 | 460 | 591 |
| Cellcept | 337 | 347 | 370 | 430 | 441 |
| Avastin | 235 | 238 | 260 | 347 | 486 |
| Pegasys | 296 | 299 | 325 | 355 | 350 |
| Tamiflu | 110 | 93 | 424 | 156 | 279 |
| Rocephin | 307 | 321 | 330 | 284 | 152 |
| Xeloda | 145 | 146 | 165 | 190 | 213 |
| Xenical | 145 | 137 | 147 | 165 | 162 |
| Kytril | 114 | 123 | 105 | 130 | 130 |
| Nutropin/Protropin | 110 | 113 | 110 | 122 | 116 |
| Copegus | 97 | 87 | 104 | 109 | 107 |
| Pulmozyme | 86 | 86 | 89 | 97 | 100 |
| Cymevene/Valcyte | 81 | 83 | 86 | 99 | 100 |
| Xolair | 68 | 73 | 81 | 100 | 104 |
| Neutrogin | 81 | 85 | 80 | 89 | 97 |
| Tarceva | - | 17 | 57 | 88 | 101 |
| Dilatrend | 86 | 75 | 83 | 84 | 79 |
| Activase/TNKase | 76 | 64 | 67 | 72 | 84 |
| New products not covered in Top 20 | | | | | |
| Fuzeon | 43 | 47 | 50 | 66 | 62 |
| Raptiva | 23 | 22 | 28 | 31 | 28 |
| Evista | 6 | 15 | 16 | 25 | 28 |
| Renagel | 11 | 12 | 11 | 15 | 15 |
| Boniva | - | - | - | 21 | 14 |

¹ Roche Pharmaceuticals, Genentech and Chugai combined

10. Pharmaceuticals Division quarterly product sales¹ in US in 2004 and 2005

| CHF millions | Q3 2004 | Q4 2004 | Q1 2005 | Q2 2005 | Q3 2005 |
|---|---------|---------|---------|---------|---------|
| MabThera/Rituxan | 531 | 514 | 540 | 573 | 612 |
| NeoRecormon/Epogin | - | - | - | - | - |
| Herceptin | 159 | 149 | 153 | 186 | 271 |
| Cellcept | 147 | 157 | 152 | 200 | 225 |
| Avastin | 230 | 230 | 240 | 300 | 409 |
| Pegasys | 112 | 110 | 109 | 124 | 124 |
| Tamiflu | 47 | 42 | 30 | 44 | 109 |
| Rocephin | 191 | 207 | 208 | 180 | 54 |
| Xeloda | 55 | 56 | 60 | 71 | 83 |
| Xenical | 20 | 20 | 25 | 24 | 24 |
| Kytril | 46 | 52 | 39 | 54 | 54 |
| Nutropin/Protopin | 107 | 110 | 107 | 119 | 113 |
| Copegus | 53 | 40 | 43 | 53 | 53 |
| Pulmozyme | 50 | 51 | 52 | 57 | 60 |
| Cymevene/Valcyte | 44 | 47 | 43 | 49 | 53 |
| Xolair | 68 | 73 | 81 | 100 | 104 |
| Neutrogin | - | - | - | - | - |
| Tarceva | - | 17 | 56 | 86 | 92 |
| Dilatrend | - | - | - | - | - |
| Activase/TNKase | 67 | 56 | 60 | 64 | 73 |
| New products not covered in Top 20 | | | | | |
| Fuzeon | 25 | 28 | 26 | 29 | 34 |
| Raptiva | 23 | 22 | 28 | 31 | 28 |
| Evista | - | - | - | - | - |
| Renagel | - | - | - | - | - |
| Boniva | - | - | - | 21 | 13 |

¹ Roche Pharmaceuticals and Genentech combined

11. Pharmaceuticals Division quarterly product sales¹ in Japan in 2004 and 2005

| CHF millions | Q3 2004 | Q4 2004 | Q1 2005 | Q2 2005 | Q3 2005 |
|---|---------|---------|---------|---------|---------|
| MabThera/Rituxan | 49 | 58 | 40 | 52 | 50 |
| NeoRecormon/Epogin | 199 | 220 | 168 | 209 | 203 |
| Herceptin | 28 | 31 | 25 | 31 | 32 |
| Cellcept | 6 | 7 | 6 | 7 | 7 |
| Avastin | - | - | - | - | - |
| Pegasys | 22 | 25 | 19 | 23 | 23 |
| Tamiflu | - | 15 | 260 | 3 | 2 |
| Rocephin | 12 | 16 | 15 | 15 | 14 |
| Xeloda | 6 | 8 | 6 | 8 | 8 |
| Xenical | - | - | - | - | - |
| Kytril | 31 | 37 | 28 | 35 | 35 |
| Nutropin/Protropin | - | - | - | - | - |
| Copegus | - | - | - | - | - |
| Pulmozyme | - | - | - | - | - |
| Cymevene/Valcyte | - | - | - | - | - |
| Xolair | - | - | - | - | - |
| Neutrogin | 81 | 85 | 80 | 89 | 97 |
| Tarceva | - | - | - | - | - |
| Dilatrend | - | - | - | - | - |
| Activase/TNKase | - | - | - | - | - |
| New products not covered in Top 20 | | | | | |
| Fuzeon | - | - | - | - | - |
| Raptiva | - | - | - | - | - |
| Evista | 6 | 15 | 16 | 25 | 28 |
| Renagel | 11 | 12 | 11 | 15 | 15 |
| Boniva | - | - | - | - | - |

¹ Chugai

12. Pharmaceuticals Division quarterly product sales in Europe/Rest of World¹ in 2004 and 2005

| CHF millions | Q3 2004 | Q4 2004 | Q1 2005 | Q2 2005 | Q3 2005 |
|---|---------|---------|---------|---------|---------|
| MabThera/Rituxan | 297 | 305 | 349 | 390 | 395 |
| NeoRecormon/Epogin | 329 | 314 | 348 | 361 | 361 |
| Herceptin | 186 | 198 | 213 | 243 | 288 |
| Cellcept | 184 | 183 | 212 | 223 | 209 |
| Avastin | 5 | 8 | 20 | 47 | 77 |
| Pegasys | 162 | 164 | 197 | 208 | 203 |
| Tamiflu | 63 | 36 | 134 | 109 | 168 |
| Rocephin | 104 | 98 | 107 | 89 | 84 |
| Xeloda | 84 | 82 | 99 | 111 | 122 |
| Xenical | 125 | 117 | 122 | 141 | 138 |
| Kytril | 37 | 34 | 38 | 41 | 41 |
| Nutropin/Protropin | 3 | 3 | 3 | 3 | 3 |
| Copegus | 44 | 47 | 61 | 56 | 54 |
| Pulmozyme | 36 | 35 | 37 | 40 | 40 |
| Cymevene/Valcyte | 37 | 36 | 43 | 50 | 47 |
| Xolair | - | - | - | - | - |
| Neutrogin | - | - | - | - | - |
| Tarceva | - | - | 1 | 2 | 9 |
| Dilatrend | 86 | 75 | 83 | 84 | 79 |
| Activase/TNKase | 9 | 8 | 7 | 8 | 11 |
| New products not covered in Top 20 | | | | | |
| Fuzeon | 18 | 19 | 24 | 37 | 28 |
| Raptiva | - | - | - | - | - |
| Evista | - | - | - | - | - |
| Renagel | - | - | - | - | - |
| Boniva | - | - | - | - | 1 |

¹ Roche Pharmaceuticals